Zoetis (NYSE:ZTS) Shares Unloaded Rep. Julie Johnson

Posted by Danessa Lincoln on May 18th, 2025

Representative Julie Johnson (D-Texas) recently sold shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on May 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on April 1st. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 4/30/2025.
Sold $1,001 – $15,000 in shares of Blackstone (NYSE:BX) on 4/22/2025.
Purchased $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 4/22/2025.
Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 4/15/2025.
Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 4/11/2025.
Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 4/11/2025.
Sold $1,001 – $15,000 in shares of DT Midstream (NYSE:DTM) on 4/7/2025.
Sold $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 4/7/2025.
Sold $1,001 – $15,000 in shares of Howmet Aerospace (NYSE:HWM) on 4/7/2025.
Sold $1,001 – $15,000 in shares of Carlisle Companies (NYSE:CSL) on 4/7/2025.

Zoetis Trading Up 1.7%

Shares of ZTS opened at $163.03 on Friday. The stock’s 50-day moving average is $156.46 and its two-hundred day moving average is $165.31. The stock has a market cap of $72.58 billion, a PE ratio of 29.80, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.20 billion. During the same quarter in the previous year, the firm posted $1.38 earnings per share. The company’s revenue was up 1.4% compared to the same quarter last year. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent analyst reports. Stifel Nicolaus cut their price target on Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Monday, April 14th. Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. UBS Group lowered their price objective on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Piper Sandler boosted their price objective on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. Finally, StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and a consensus price target of $212.75.

Check Out Our Latest Stock Report on ZTS

Hedge Funds Weigh In On Zoetis

Several institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Zoetis by 0.5% during the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after purchasing an additional 189,287 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Zoetis by 1.8% during the fourth quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock valued at $1,726,075,000 after purchasing an additional 190,137 shares during the last quarter. Polen Capital Management LLC grew its holdings in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Zoetis by 78.5% during the fourth quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after purchasing an additional 78,508 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Zoetis

(Get Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.